Alligator Bioscience (ATORX) R&D Day 2025 summary

Pipeline overview and program updates

• Mitazalimab is phase III ready, targeting first-line metastatic pancreatic cancer with demonstrated efficacy and long-term survival benefit; expansion into additional GI and non-GI cancers is planned via investigator-initiated trials.

• ATOR-4066, a bispecific follow-up to mitazalimab, is in preclinical development for more targeted applications.

• HLX22, a HER2 antibody, is in phase III for gastric cancer and phase II for breast cancer, with Alligator holding future royalty rights.

Clinical trial data and development milestones

• OPTIMIZE-1 phase II trial showed mitazalimab plus FOLFIRINOX tripled 24-month survival rates and doubled duration of response compared to historical controls, with a median overall survival of 14.9 months.

• Safety profile is favorable, with no added toxicities or cytokine release syndrome observed.

• Biomarker analyses confirm immune activation correlates with improved survival and may inform patient selection.

• Final OPTIMIZE-1 readout is expected in Q3 2025.

R&D strategy and innovation priorities

• Focus on expanding mitazalimab's clinical footprint through investigator-initiated trials in various tumor types and combinations with other modalities.

• Ongoing biomarker research to refine patient selection and optimize clinical outcomes.

• Continued development of proprietary antibody technologies and bispecific formats.